

C\*

FILE 'HOME' ENTERED AT 10:57:57 ON 08 APR 2008

=> file medline embase caplus biosis uspatfull  
COST IN U.S. DOLLARS                      SINCE FILE          TOTAL  
   ENTRY          SESSION  
FULL ESTIMATED COST                                      0.21      0.21

FILE 'MEDLINE' ENTERED AT 10:58:34 ON 08 APR 2008

FILE 'EMBASE' ENTERED AT 10:58:34 ON 08 APR 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 10:58:34 ON 08 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:58:34 ON 08 APR 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 10:58:34 ON 08 APR 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (interferon-beta or IFN-beta or (interferon (w) beta0))

UNMATCHED LEFT PARENTHESIS '(INTERFERON'

The number of right parentheses in a query must be equal to the  
number of left parentheses.

=> s (interferon-beta or IFN-beta or (interferon (w) beta))

L1     41061 (INTERFERON-BETA OR IFN-BETA OR (INTERFERON (W) BETA))

=> l1 (s) (nephritis or (nephrotic (w) syndrome))

L1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 (s) (nephritis or (nephrotic (w) syndrome))

L2     55 L1 (S) (NEPHRITIS OR (NEPHROTIC (W) SYNDROME))

=> duplicate remove l2

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, CAPLUS, BIOSIS, USPATFULL'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L2

L3     41 DUPLICATE REMOVE L2 (14 DUPLICATES REMOVED)

=> d l3 1- ibib, abs

YOU HAVE REQUESTED DATA FROM 41 ANSWERS - CONTINUE? Y/(N):y

L3    ANSWER 1 OF 41    USPATFULL on STN

ACCESSION NUMBER:    2008:10294    USPATFULL <<LOGINID::20080408>>

TITLE:                Single domain antibodies against tnfr1 and methods of  
                         use therefor

INVENTOR(S): Brewis, Neil D., HAUXTON, UNITED KINGDOM  
PATENT ASSIGNEE(S): Domantis Limited, Cambridge, UNITED KINGDOM, CB4 0WF  
(non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2008008713 A1 20080110  
APPLICATION INFO.: US 2005-664542 A1 20051007 (11)  
WO 2005-GB3873 20051007  
20070906 PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-985847, filed  
on 10 Nov 2004, PENDING Continuation-in-part of Ser.  
No. WO 2005-GB4253, filed on 8 Oct 2004, UNKNOWN  
Continuation-in-part of Ser. No. WO 2005-GB5646, filed  
on 24 Dec 2003, UNKNOWN Continuation-in-part of Ser.  
No. WO 2005-GB2804, filed on 30 Jun 2003, UNKNOWN  
Continuation-in-part of Ser. No. WO 2005-GB3014, filed  
on 28 Jun 2002, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: GB 2002-30202 20021227  
GB 2003-27706 20031128

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA  
ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US

NUMBER OF CLAIMS: 105

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 92 Drawing Page(s)

LINE COUNT: 8197

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are concentrated preparations comprising single immunoglobulin  
variable domain polypeptides that bind target antigen with high affinity  
and are soluble at high concentration, without aggregation or  
precipitation, providing, for example, for increased storage stability  
and the ability to administer higher therapeutic doses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 41 MEDLINE on STN

ACCESSION NUMBER: 2007636650 MEDLINE <<LOGINID::20080408>>

DOCUMENT NUMBER: PubMed ID: 17942945

TITLE: Interferon-beta: a novel way to treat  
nephrotic syndrome?.

AUTHOR: Rees Andrew J; Kain Renate

SOURCE: Journal of the American Society of Nephrology : JASN, (2007  
Nov) Vol. 18, No. 11, pp. 2797-8. Electronic Publication:  
2007-10-17.  
Journal code: 9013836. E-ISSN: 1533-3450.

PUB. COUNTRY: United States

DOCUMENT TYPE: Commentary  
Editorial

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200712

ENTRY DATE: Entered STN: 27 Oct 2007  
Last Updated on STN: 14 Dec 2007  
Entered Medline: 13 Dec 2007

L3 ANSWER 3 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2007:134425 USPATFULL <<LOGINID::20080408>>  
TITLE: Interferon assay  
INVENTOR(S): Crow, Mary K., New York, NY, UNITED STATES  
Kirou, Kyriakos, Astoria, NY, UNITED STATES  
Hua, Jing, Elmhurst, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2007117105 A1 20070524  
APPLICATION INFO.: US 2006-431775 A1 20060509 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2005-680931P 20050512 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY,  
10150-5257, US  
NUMBER OF CLAIMS: 32  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Page(s)  
LINE COUNT: 2372  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and reporter cell assays for determining the ability of a patient sample to induce interferon target gene expression in interferon responsive cells. These methods will be useful for detecting, diagnosing, and monitoring those who have or are at risk of various autoimmune disorders or diseases, including systemic lupus erythematosus (SLE) and Sjogren's syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2007:120509 USPATFULL <<LOGINID::20080408>>  
TITLE: Ligand that has binding specificity for IL-4 and/or  
IL-13  
INVENTOR(S): Tomlinson, Ian M., Cambridge, UNITED KINGDOM  
Holmes, Steve, Cambridge, UNITED KINGDOM  
Moulder, Kevin, Cambridge, UNITED KINGDOM  
PATENT ASSIGNEE(S): Domants Limited, Cambridge, UNITED KINGDOM (non-U.S.  
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2007104710 A1 20070510  
APPLICATION INFO.: US 2006-338863 A1 20060124 (11)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-23959, filed  
on 28 Dec 2004, PENDING Continuation of Ser. No. WO  
2003-GB2804, filed on 30 Jun 2003, UNKNOWN  
Continuation-in-part of Ser. No. WO 2002-GB3014, filed  
on 28 Jun 2002, UNKNOWN

NUMBER DATE  
-----  
PRIORITY INFORMATION: GB 2003-27706 20031128  
GB 2002-30202 20021227  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA  
ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 17 Drawing Page(s)  
LINE COUNT: 7345  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides a dual-specific ligand comprising a first  
immunoglobulin variable domain having a first binding specificity and a  
complementary or non-complementary immunoglobulin variable domain having  
a second binding specificity.  
  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L3 ANSWER 5 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2007:107678 USPATFULL <<LOGINID::20080408>>  
TITLE: Ligand  
INVENTOR(S): Moulder, Kevin, Cambridge, UNITED KINGDOM  
Tomlinson, Ian, Cambridge, UNITED KINGDOM  
PATENT ASSIGNEE(S): Domantis Limited (non-U.S. corporation)

NUMBER KIND DATE  
-----  
PATENT INFORMATION: US 2007093651 A1 20070426  
APPLICATION INFO.: US 2006-501522 A1 20060808 (11)  
RELATED APPLN. INFO.: Division of Ser. No. US 2004-23959, filed on 28 Dec  
2004, PENDING Continuation of Ser. No. WO 2003-GB2804,  
filed on 30 Jun 2003, UNKNOWN Continuation-in-part of  
Ser. No. US 2003-744774, filed on 23 Dec 2003, PENDING  
Continuation of Ser. No. WO 2002-GB3014, filed on 28  
Jun 2002, UNKNOWN

NUMBER DATE  
-----  
PRIORITY INFORMATION: GB 2002-30202 20021227  
GB 2001-15841 20010628  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111  
HUNTINGTON AVENUE, BOSTON, MA, 02199, US  
NUMBER OF CLAIMS: 1  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 17 Drawing Page(s)  
LINE COUNT: 7018  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides a dual-specific ligand comprising a first  
immunoglobulin variable domain having a first binding specificity and a  
complementary or non-complementary immunoglobulin variable domain having  
a second binding specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2007:88629 USPATFULL <<LOGINID::20080408>>

TITLE: Stem cell expansion and uses

INVENTOR(S): Reading, Christopher L., San Diego, CA, UNITED STATES  
Frincke, James M., San Diego, CA, UNITED STATES  
Dowding, Charles, San Diego, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2007077201	A1	20070405
---------------------	---------------	----	----------

APPLICATION INFO.:	US 2006-389294	A1	20060325 (11)
--------------------	----------------	----	---------------

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2005-241670, filed  
on 29 Sep 2005, PENDING

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2004-614869P	20040929 (60)
-----------------------	-----------------	---------------

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE  
MALL,

SUITE 400, SAN DIEGO, CA, 92121, US

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

LINE COUNT: 18130

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods to manipulate stem cells in vivo and in  
vitro to treat, e.g., a conditions where cell or tissue repair is  
needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2007:29699 USPATFULL <<LOGINID::20080408>>

TITLE: Therapies for renal failure using interferon-beta

INVENTOR(S): Lobb, Roy R., Westwood, MA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2007025965	A1	20070201
---------------------	---------------	----	----------

APPLICATION INFO.:	US 2003-521513	A1	20030717 (10)
--------------------	----------------	----	---------------

WO 2003-US22440	20030717
-----------------	----------

20051118 PCT 371 date

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2002-396393P	20020717 (60)
-----------------------	-----------------	---------------

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE  
CENTER WEST,

155 SEAPORT BLVD, BOSTON, MA, 02110, US

NUMBER OF CLAIMS: 32

EXEMPLARY CLAIM: 1-69  
NUMBER OF DRAWINGS: 13 Drawing Page(s)  
LINE COUNT: 3109  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, glomerulonephritis or chronic renal failure. The methods involve the administration of IFN- $\beta$  therapeutics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2007:17006 USPATFULL <<LOGINID::20080408>>  
TITLE: Steroid analogs and characterization and treatment  
methods  
INVENTOR(S): Reading, Christopher L., San Diego, CA, UNITED STATES  
Frincke, James M., San Diego, CA, UNITED STATES  
Dowding, Charles, San Diego, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2007014719	A1	20070118
APPLICATION INFO.:	US 2005-241670	A1	20050929 (11)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2004-614869P 20040929 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,

SUITE 400, SAN DIEGO, CA, 92121, US

NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
LINE COUNT: 24267  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods to characterize exemplified compounds such as 3b, 17b-dihydroxyandrost-1,5,11-triene and 3b, 17b-dihydroxy-17a-ethynylandrost-1,5,11-triene and to the use of described compounds to ameliorate or treat a condition such as thrombocytopenia, inflammation or other exemplified conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2007:7703 USPATFULL <<LOGINID::20080408>>  
TITLE: Aromatic amine derivatives, their production and use  
INVENTOR(S): Oi, Satoru, Nara, JAPAN  
Suzuki, Nobuhiro, Tsukuba, JAPAN  
Aso, Kazuyoshi, Takatsuki, JAPAN  
Banno, Yoshihiro, Takatsuki, JAPAN  
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN  
(non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----  
PATENT INFORMATION: US 7160887 B1 20070109  
WO 2000023420 20000427  
APPLICATION INFO.: US 1999-807081 19991019 (9)  
WO 1999-JP5755 19991019  
20010406 PCT 371 date

NUMBER DATE  
-----

PRIORITY INFORMATION: JP 1998-298940 19981020  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Mckenzie, Thomas  
ASSISTANT EXAMINER: Robinson, Binta  
LEGAL REPRESENTATIVE: Ramesh, Elaine M., Chao, Mark  
NUMBER OF CLAIMS: 18  
EXEMPLARY CLAIM: 1  
LINE COUNT: 9620  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds of a formula:

##STR1## wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; R.sup.1 represents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; R.sup.2 represents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents --CO--, --CON(R.sup.a)--, COO--, N(R.sup.a)CON(R.sup.b)--, --N(R.sup.a)COO--, --N(R.sup.a)SO.sub.2--, N(R.sup.a)--, --O--, --S--, --SO-- or --SO.sub.2-- (in which R.sup.a and R.sup.b each independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from;

- (i) a C.sub.1-6 alkyl group,
- (ii) a halogeno-C.sub.1-6 alkyl group,
- (iii) a phenyl group,
- (iv) a benzyl group,
- (v) an optionally-substituted amino group,
- (vi) an optionally-substituted hydroxy group, and
- (vii) a carbamoyl or thiocarbamoyl group optionally substituted by:
  - <1> a C.sub.1-6 alkyl group,
  - <2> an optionally-substituted phenyl group, or
  - <3> an optionally-substituted heterocyclic group, and optionally interrupted by --O-- or --S--; X represents an oxygen atom, an optionally-oxidized sulfur atom, an optionally-substituted nitrogen atom, or an optionally-substituted divalent hydrocarbon group; Y represents two hydrogen atoms, an oxygen atom or a sulfur atom; . . . means that R.sup.2 may be bonded to the atom on Ring B to form a ring, or their salts, and a method for producing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007636673 MEDLINE <<LOGINID::20080408>>

DOCUMENT NUMBER: PubMed ID: 17942968

TITLE: Interferon-beta reduces proteinuria in experimental  
glomerulonephritis.

AUTHOR: Satchell Simon C; Buchatska Olena; Khan Sarah B; Bhangal  
Gurjeet; Tasman Candida H; Saleem Moin A; Baker Darren P;  
Lobb Roy R; Smith Jennifer; Cook H Terence; Mathieson Peter  
W; Pusey Charles D

CORPORATE SOURCE: Academic Renal Unit, University of Bristol, Southmead  
Hospital, Bristol, UK. s.c.satchell@bristol.ac.uk

CONTRACT NUMBER: 075731

SOURCE: Journal of the American Society of Nephrology : JASN, (2007  
Nov) Vol. 18, No. 11, pp. 2875-84. Electronic Publication:  
2007-10-17.

Journal code: 9013836. E-ISSN: 1533-3450.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200712

ENTRY DATE: Entered STN: 27 Oct 2007

Last Updated on STN: 14 Dec 2007

Entered Medline: 13 Dec 2007

AB Interferon-beta (IFN-beta) is a multifunctional cytokine with immunomodulatory properties. We examined the effect of IFN-beta in three separate rat models of glomerular injury and in cultured human glomerular endothelial cells and podocytes. In nephrotoxic nephritis in WKY rats, recombinant rat IFN-beta started either at induction or after establishment of disease significantly reduced 24-h proteinuria by up to 73% and 51%, respectively, but did not affect serum creatinine. There was a slight reduction in numbers of glomerular macrophages, but no difference in glomerular or tubulointerstitial scarring. In Thy-1 nephritis in Lewis rats, IFN-beta started at induction of disease reduced proteinuria by up to 66% with no effect on numbers of glomerular macrophages, but a reduced number of proliferating cells. In puromycin nephropathy in Wistar rats, IFN-beta started at induction of disease reduced proteinuria by up to 93%, but had no effect on glomerular histology. In cultured cells, human IFN-beta-1a had a dramatic effect on barrier properties, increasing electrical resistance across monolayers of either glomerular endothelial cells or podocytes and decreasing trans-monolayer passage of albumin. In conclusion, these results show that IFN-beta reduces proteinuria in three different rat models of glomerular injury and that its anti-proteinuric action may result from direct effects on cells that comprise the glomerular filtration barrier. These data indicate that IFN-beta may have potential as a therapeutic agent in proteinuric renal disease.

L3 ANSWER 11 OF 41 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN DUPLICATE 2

ACCESSION NUMBER: 2007539610 EMBASE <<LOGINID::20080408>>

TITLE: Interferon-b: A novel way to treat  
nephrotic syndrome?.

AUTHOR: Rees, Andrew J., Prof. (correspondence); Kain, Renate

CORPORATE SOURCE: Institute of Clinical Pathology, Medical University of  
Vienna, Wahringer Gurtel 18-20, A-1080 Vienna, Austria.



andrew.rees@mediuniwien.ac.at  
SOURCE: Journal of the American Society of Nephrology, (Nov 2007)  
Vol. 18, No. 11, pp. 2797-2798.  
Refs: 15  
ISSN: 1046-6673 CODEN: JASNEU  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Editorial  
FILE SEGMENT: 028 Urology and Nephrology  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
ENTRY DATE: Entered STN: 19 Nov 2007  
Last Updated on STN: 19 Nov 2007

L3 ANSWER 12 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2006:321793 USPATFULL <<LOGINID::20080408>>  
TITLE: Methods and compositions related to joint inflammation  
diseases  
INVENTOR(S): Ritchlin, Christopher T., Canadagua, NY, UNITED STATES  
Haas-Smith, Sally, Ridgefield, CT, UNITED STATES  
Schwarz, Edward, Rochester, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006275834 A1 20061207  
APPLICATION INFO.: US 2004-548389 A1 20040315 (10)  
WO 2004-US8168 20040315  
20060726 PCT 371 date  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-799345, filed  
on 12 Mar 2004, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 2003-454573P 20030314 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE  
STREET, ATLANTA, GA, 30309-3915, US  
NUMBER OF CLAIMS: 93  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 34 Drawing Page(s)  
LINE COUNT: 6849  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are compositions and methods related to joint inflammation  
diseases. Disclosed is the relationship between osteoclasts and  
inflammatory joint diseases and osteoclast cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2006:301052 USPATFULL <<LOGINID::20080408>>  
TITLE: Ligand  
INVENTOR(S): Winter, Greg, Great Court, UNITED KINGDOM  
Tomlinson, Ian, Abington, UNITED KINGDOM  
Ignatovich, Olga, Abington, UNITED KINGDOM  
Woolven, Ben, Abington, UNITED KINGDOM

Jones, Philip, Impington, UNITED KINGDOM  
PATENT ASSIGNEE(S): Domantis Limited (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2006257406 A1 20061116  
APPLICATION INFO.: US 2005-141661 A1 20050531 (11)  
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2003-GB5646, filed on 24  
Dec 2003, UNKNOWN

NUMBER DATE

-----  
PRIORITY INFORMATION: GB 2002-30202 20021227  
GB 2003-27706 20031128  
WO 2003-GB2804 20030630  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111  
HUNTINGTON AVENUE, BOSTON, MA, 02199, US  
NUMBER OF CLAIMS: 48  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 7644  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides a dual-specific ligand comprising a first  
immunoglobulin variable domain having a first binding specificity for a  
target ligand and a complementary or non-complementary immunoglobulin  
variable domain having a second binding specificity for a receptor of  
the target ligand.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2006:288496 USPATFULL <<LOGINID::20080408>>  
TITLE: Methods and compositions for evaluating graft survival  
in a solid organ transplant recipient  
INVENTOR(S): Sarwal, Minnie S., Portola Valley, CA, UNITED STATES  
Mansfield, Elaine S., Sunnyvale, CA, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2006246485 A1 20061102  
APPLICATION INFO.: US 2006-375681 A1 20060313 (11)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2005-662083P 20050314 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY  
AVENUE,  
SUITE 200, EAST PALO ALTO, CA, 94303, US  
NUMBER OF CLAIMS: 26  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 4 Drawing Page(s)  
LINE COUNT: 1992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for evaluating a subject for graft survival, e.g., in terms of predicting graft survival, identifying the presence of a deleterious graft condition, such as CAN and DT, identifying the severity and class of acute rejection, etc, in a subject are provided. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is assayed, e.g., at the nucleic acid and/or protein level, to evaluate the subject. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:125468 USPATFULL <<LOGINID::20080408>>

TITLE: Ligand

INVENTOR(S): Winter, Greg, Cambridge, UNITED KINGDOM  
Tomlinson, Ian, Cambridgeshire, UNITED KINGDOM  
Ignatovich, Olga, Cambridgeshire, UNITED KINGDOM  
Holt, Lucy, Cambridgeshire, UNITED KINGDOM  
De Angelis, Elena, Cambridgeshire, UNITED KINGDOM  
Jones, Philip C., Abington, UNITED KINGDOM

PATENT ASSIGNEE(S): Domantis Limited (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2006106203 A1 20060518

APPLICATION INFO.: US 2004-23959 A1 20041228 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2003-GB2804, filed on 30  
Jun 2003, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: WO 2002-GB3014 20020628

GB 2002-30202 20021227

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111  
HUNTINGTON AVENUE, BOSTON, MA, 02199, US

NUMBER OF CLAIMS: 83

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Page(s)

LINE COUNT: 6926

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:98549 USPATFULL <<LOGINID::20080408>>

TITLE: Interferon beta-like molecules for treatment of stroke

INVENTOR(S): Glazer, Steven, Copenhagen N, DENMARK

Sager, Thomas, Smørum, DENMARK

NUMBER KIND DATE

PATENT INFORMATION: US 2006083715 A1 20060420  
APPLICATION INFO.: US 2003-506954 A1 20030228 (10)  
WO 2003-DK127 20030228  
20050609 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: DK 2002-371 20020312  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT,  
515

GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US

NUMBER OF CLAIMS: 40  
EXEMPLARY CLAIM: 1-7

LINE COUNT: 2700

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to use of interferon beta-like polypeptides for treatment of stroke or transient ischemic attack in a primate, preferably in a human. More particularly, the interferon beta-like polypeptides differs from the amino acid sequence of wild-type human IFNB (SEQ ID NO:2) in that at least one glycosylation site, preferably at least one in vivo N-glycosylation site has been introduced. Optionally the interferon beta-like polypeptides are PEGylated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:86142 USPATFULL <<LOGINID::20080408>>

TITLE: Compositions and methods for treating inflammatory disorders

INVENTOR(S): Ignatovich, Olga, Cambridge, UNITED KINGDOM  
de Wildt, Rudolf Maria Theodora, Cambridge, UNITED KINGDOM

Woolven, Benjamin, Cambridge, UNITED KINGDOM

Grant, Steven, Cambridge, UNITED KINGDOM

Jones, Philip C., Cambridge, UNITED KINGDOM

Basran, Amrik, Cambridge, UNITED KINGDOM

Brewis, Neil, Cambridge, UNITED KINGDOM

PATENT ASSIGNEE(S): Domantis Limited (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2006073141 A1 20060406  
APPLICATION INFO.: US 2005-98758 A1 20050404 (11)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-925366, filed on 24 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2003-744774, filed on 23 Dec 2003, PENDING Continuation-in-part of Ser. No. WO 2003-GB2804, filed on 30 Jun 2003, UNKNOWN Continuation-in-part of Ser. No. WO 2002-GB3014, filed on 28 Jun 2002, UNKNOWN

Continuation-in-part of Ser. No. WO 2004-GB2829, filed  
on 30 Jun 2004, UNKNOWN Continuation-in-part of Ser.  
No. WO 2003-GB5646, filed on 24 Dec 2003, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: GB 2002-30202 20021227

GB 2001-115841 20010628

GB 2003-27706 20031128

US 2004-535076P 20040108 (60)

US 2003-509613P 20031008 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111  
HUNTINGTON AVENUE, BOSTON, MA, 02199, US

NUMBER OF CLAIMS: 66

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 14459

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions and methods for treating  
inflammatory disorders. More specifically, the invention relates to  
antibody compositions and their use in the treatment of inflammatory  
disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:74872 USPATFULL <<LOGINID::20080408>>

TITLE: Ligand

INVENTOR(S): Moulder, Kevin, Cambridge, UNITED KINGDOM  
Tomlinson, Ian, Cambridge, UNITED KINGDOM

PATENT ASSIGNEE(S): Domantis Limited (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2006063921 A1 20060323

APPLICATION INFO.: US 2005-217919 A1 20050901 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2004-23959, filed on 28 Dec  
2004, PENDING Continuation of Ser. No. WO 2003-GB2804,  
filed on 30 Jun 2003, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: GB 2002-30202 20021227

WO 2002-GB3014 20020628

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111  
HUNTINGTON AVENUE, BOSTON, MA, 02199, US

NUMBER OF CLAIMS: 94

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Page(s)

LINE COUNT: 6936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a dual-specific ligand comprising a first

immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:3480 USPATFULL <<LOGINID::20080408>>

TITLE: Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor

INVENTOR(S): Brewis, Neil D., Hauxton, UNITED KINGDOM  
Woolven, Benjamin P., Bedford, UNITED KINGDOM  
Holmes, Steve, Great Chishill, UNITED KINGDOM  
Tomlinson, Ian M., Great Shelford, UNITED KINGDOM

PATENT ASSIGNEE(S): Domantis Limited, Cambridge, UNITED KINGDOM (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2006002935 A1 20060105

APPLICATION INFO.: US 2004-985847 A1 20041110 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2004-GB4253, filed on 8 Oct 2004, UNKNOWN Continuation-in-part of Ser. No. WO 2003-GB5646, filed on 24 Dec 2003, UNKNOWN Continuation-in-part of Ser. No. WO 2003-GB2804, filed on 30 Jun 2003, UNKNOWN Continuation-in-part of Ser. No. WO 2002-GB3014, filed on 28 Jun 2002, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: GB 2002-30202 20021227  
GB 2003-27706 20031128

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US

NUMBER OF CLAIMS: 32

EXEMPLARY CLAIM: 1-44

NUMBER OF DRAWINGS: 68 Drawing Page(s)

LINE COUNT: 6630

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1114172 CAPLUS <<LOGINID::20080408>>

DOCUMENT NUMBER: 146:204506

TITLE: Genetic susceptibility to PolyI:C-induced

IFNa/b-dependent accelerated disease in  
lupus-prone mice

AUTHOR(S): Jorgensen, T. N.; Thurman, J.; Izui, S.; Falta, M. T.;  
Metzger, T. E.; Flannery, S. A.; Kappler, J.; Marrack,  
P.; Kotzin, B. L.

CORPORATE SOURCE: Division of Clinical Immunology, University of  
Colorado Health Sciences Center, Denver, CO, 80206,  
USA

SOURCE: Genes and Immunity (2006), 7(7), 555-567  
CODEN: GEIMA2; ISSN: 1466-4879

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown  
etiol. Assocns. between viral infections and the onset of SLE have been  
suggested, and recent studies have provided evidence that type I  
interferons (IFNa/b) might play a role in the SLE disease  
process. Viruses and interferons have also been implicated in mouse  
models of SLE. We generated a model of accelerated proteinuria, in which  
lupus-prone mice were injected repeatedly with polyinosinic:polycytidylic  
acid (polyI:C), mimicking exposure to virus-derived double stranded RNA  
(dsRNA), leading to the production of IFNa/b. PolyI:C-treated  
(B6.Nba2 + NZW)F1 and (B6 + NZW)F1 hybrid mice developed  
significantly increased levels of anti-dsDNA autoantibodies,  
characteristic of lupus. Most significantly, polyI:C-treated (B6.Nba2  
+ NZW)F1 mice, but not (B6 + NZW)F1 or parental strains,  
developed lupus-like nephritis in an accelerated fashion, which was  
dependent on IFNa/b and associated with elevated deposition of  
total IgG, IgG2a and complement factor C3 in the glomerular capillary  
walls. These data suggest that reagents, which increase the levels of  
endogenous IFNa/b (directly or indirectly), can accelerate the  
course of lupus-like nephritis, the development of which is dependent on  
the presence of both NZW- and Nba2-encoded genes.

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 41 MEDLINE on STN DUPLICATE 3

ACCESSION NUMBER: 2006578400 MEDLINE <<LOGINID::20080408>>

DOCUMENT NUMBER: PubMed ID: 17009081

TITLE: Nephrotic syndrome associated with  
interferon-beta-1b therapy for multiple  
sclerosis.

AUTHOR: Kumasaka Ryuichiro; Nakamura Norio; Shirato Kenichi; Fujita  
Takashi; Murakami Reiichi; Shimada Michiko; Nakamura  
Masayuki; Osawa Hiroshi; Yamabe Hideaki; Okumura Ken

CORPORATE SOURCE: The Second Department of Internal Medicine, Hiroaki  
University School of Medicine, 5 Zaifu-cho, Hiroaki,  
Aomori, 036-8562, Japan.. rkuma-cc@umin.ac.jp

SOURCE: Clinical and experimental nephrology, (2006 Sep) Vol. 10,  
No. 3, pp. 222-5.  
Journal code: 9709923. ISSN: 1342-1751.

PUB. COUNTRY: Japan

DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200612  
ENTRY DATE: Entered STN: 30 Sep 2006  
Last Updated on STN: 19 Dec 2006  
Entered Medline: 11 Dec 2006

AB A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon ( IFN)-beta-1b (subcutaneous administration). She had taken no drug except for the IFN-beta-1b. Because nephrotic syndrome may be induced by IFN therapy, the IFN was stopped. Percutaneous renal biopsy revealed that she had minimal change nephrotic syndrome. As nephrotic-range proteinuria, hypoalbuminemia, and general edema were worsening even 2 weeks after cessation of the drug, oral corticosteroid therapy (prednisolone 40 mg/day) was started. The nephrotic syndrome was treated successfully with prednisolone. The dosage of prednisolone was tapered, without a relapse, and then the corticosteroid therapy was stopped. IFN-beta-1b therapy was then resumed, and the patient is in remission for both nephrotic syndrome and MS. Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.

L3 ANSWER 22 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2005:312046 USPATFULL <<LOGINID::20080408>>  
TITLE: Compositions and methods for treating inflammatory disorders  
INVENTOR(S): Ignatovich, Olga, Cambridge, UNITED KINGDOM  
de Wildt, Rudolf Maria Theodora, Cambridge, UNITED KINGDOM  
Woolven, Benjamin, Cambridge, UNITED KINGDOM  
Grant, Steven, Cambridge, UNITED KINGDOM  
Jones, Philip C., Cambridge, UNITED KINGDOM  
Basran, Amrik, Cambridge, UNITED KINGDOM  
Brewis, Neil, Cambridge, UNITED KINGDOM  
PATENT ASSIGNEE(S): Domantis Limited (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005271663 A1 20051208  
APPLICATION INFO.: US 2004-925366 A1 20040824 (10)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-744774, filed on 23 Dec 2003, PENDING Continuation-in-part of Ser. No. WO 2003-GB2804, filed on 30 Jun 2003, UNKNOWN Continuation-in-part of Ser. No. WO 2002-GB3014, filed on 28 Jun 2002, UNKNOWN Continuation-in-part of Ser. No. WO 2004-GB2829, filed on 30 Jun 2004, UNKNOWN Continuation-in-part of Ser. No. WO 2003-GB5646, filed on 24 Dec 2003, UNKNOWN

NUMBER DATE

-----  
PRIORITY INFORMATION: GB 2002-30202 20021227  
GB 2001-115841 20010628  
GB 2003-27706 20031128  
US 2004-535076P 20040108 (60)  
US 2003-509613P 20031008 (60)



DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111  
HUNTINGTON AVENUE, BOSTON, MA, 02199, US  
NUMBER OF CLAIMS: 158  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Page(s)  
LINE COUNT: 13839  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to compositions and methods for treating  
inflammatory disorders. More specifically, the invention relates to  
antibody compositions and their use in the treatment of inflammatory  
disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2005:281582 USPATFULL <<LOGINID::20080408>>  
TITLE: Use of compounds having ccr antagonism  
INVENTOR(S): Tsuchimori, Noboru, Amagasaki-shi Hyogo, JAPAN  
Iizawa, Yuji, Muko-shi, JAPAN  
Shiraishi, Mitsuru, Amagasaki-shi, JAPAN  
Sugihara, Yoshihiro, Ikoma-shi Nara, JAPAN

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005245537 A1 20051103  
APPLICATION INFO.: US 2003-511112 A1 20030423 (10)  
WO 2003-JP5172 20030423  
20041021 PCT 371 date

NUMBER DATE

-----  
PRIORITY INFORMATION: JP 2002-122832 20020424  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC,  
INTELLECTUAL  
PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500,  
LINCOLNSHIRE, IL, 60069, US

NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
LINE COUNT: 7536  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB It is intended to provide preventives/remedies for graft-versus-host  
disease and/or rejection in organ or bone marrow transplantation,  
rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic  
cerebral cell injury, myocardial infarction, chronic nephritis and  
arteriosclerosis. The above object can be achieved by  
preventives/remedies for graft-versus-host disease and/or rejection in  
organ or bone marrow transplantation, rheumatoid arthritis, autoimmune  
diseases, allergic diseases, ischemic cerebral cell injury, myocardial  
infarction, chronic nephritis and arteriosclerosis characterized by  
containing a specific compound having a CCR (CC chemokine receptor)  
antagonism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:112372 USPATFULL <<LOGINID::20080408>>

TITLE: Full-length human cDNAs encoding potentially secreted proteins

INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE

NUMBER KIND DATE

PATENT INFORMATION: US 2005096458 A1 20050505

US 7271243 B2 20070918

APPLICATION INFO.: US 2003-643836 A1 20030819 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-731872, filed on 7 Dec 2000, ABANDONED

NUMBER DATE

PRIORITY INFORMATION: US 1999-169629P 19991208 (60)

US 2000-187470P 20000306 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 28075

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 41 MEDLINE on STN DUPLICATE 4

ACCESSION NUMBER: 2005573861 MEDLINE <<LOGINID::20080408>>

DOCUMENT NUMBER: PubMed ID: 16221871

TITLE: Interferon-beta: a therapeutic for autoimmune lupus in MRL-Fas<sup>lpr</sup> mice.

AUTHOR: Schwarting Andreas; Paul Kathrin; Tschirner Stefan; Menke Julia; Hansen Torsten; Brenner Walburgis; Kelley Vicki Rubin; Relle Manfred; Galle Peter R

CORPORATE SOURCE: First Department of Medicine, Johannes-Gutenberg University of Mainz, Langenbeckstrasse 1, Mainz 55131, Germany..  
aschwart@mail.uni-mainz.de

CONTRACT NUMBER: R01-DK 36149 (United States NIDDK)

R01-DK 52369 (United States NIDDK)

SOURCE: Journal of the American Society of Nephrology : JASN, (2005

Nov) Vol. 16, No. 11, pp. 3264-72. Electronic Publication:  
2005-10-12.

Journal code: 9013836. ISSN: 1046-6673.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200603

ENTRY DATE: Entered STN: 28 Oct 2005

Last Updated on STN: 3 Mar 2006

Entered Medline: 2 Mar 2006

AB Type I interferons are associated with lupus. Genes that are regulated by IFN-alpha are upregulated in pediatric lupus patients. Gene deletion of the IFN-alpha/beta receptor in experimental lupus-like NZB mice results in reduced disease activity. Conversely, IFN-beta is a well-established treatment in multiple sclerosis, another autoimmune disease. For determining whether IFN-beta treatment is harmful or beneficial in lupus, MRL-Fas(lpr) mice were injected with this type I IFN. Treatment was initiated in MRL-Fas(lpr) mice with mild and advanced disease. IFN-beta was highly effective in prolonging survival and ameliorating the clinical (renal function, proteinuria, splenomegaly, and skin lesions), serologic (autoantibodies and cytokines), and histologic parameters of the lupus-like disease in mice that had mild and advanced disease. Several underlying mechanisms of IFN-beta therapy involving cellular (decreased T cell proliferation and infiltration of leukocytes into the kidney) and humoral (decrease in IgG3 isotypes) immune responses and a reduction in nephrogenic cytokines were identified. In conclusion, IFN-beta treatment of lupus nephritis in MRL-Fas(lpr) mice is remarkably beneficial and suggests that IFN-beta may be an appealing therapeutic candidate for subtypes of human lupus.

L3 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1244012 CAPLUS <<LOGINID::20080408>>

DOCUMENT NUMBER: 144:266826

TITLE: More targeted treatments for lupus nephritis: Is the future here?

AUTHOR(S): Kitching, A. Richard

CORPORATE SOURCE: Centre for Inflammatory Diseases, Monash Medical Centre, Monash University Department of Medicine, Clayton, Victoria, Australia

SOURCE: Journal of the American Society of Nephrology (2005), 16(11), 3146-3148

CODEN: JASNEU; ISSN: 1046-6673

PUBLISHER: American Society of Nephrology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The research of Patole et al. (2005) entitled "G-rich DNA suppresses systemic lupus" and of Schwarting et al. (2005) entitled "Interferon-beta: A therapeutic for autoimmune lupus in MRL-Fas(lpr) mice" are reviewed with commentary and refs. These two studies both use the MRLlpr/lpr mouse as a model of lupus nephritis. Patole et al. use synthetic G-rich DNA in an intervention study to block the effects of hypomethylated DNA on Toll-like receptor 9 (TLR9). Schwarting et al. report on amelioration of lupus nephritis with markedly reduced mortality in MRLlpr/lpr mice

treated with interferon-beta. These studies may point the way toward more specific therapies for this disease. However, there remain several major hurdles before more effective and targeted therapies are delivered to people with lupus nephritis.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 41 MEDLINE on STN DUPLICATE 5  
ACCESSION NUMBER: 2005548856 MEDLINE <<LOGINID::20080408>>  
DOCUMENT NUMBER: PubMed ID: 16225183  
TITLE: Nephrotic syndrome in a multiple  
sclerosis patient treated with interferon  
beta 1a.  
AUTHOR: Auty Anthony; Saleh Abdulkarim  
CORPORATE SOURCE: Division of Neurology, Department of Medicine, Shaikh  
Khalifa Medical Centre, Abu Dhabi, United Arab Emirates.  
SOURCE: The Canadian journal of neurological sciences. Le journal  
canadien des sciences neurologiques, (2005 Aug) Vol. 32,  
No. 3, pp. 366-8.  
Journal code: 0415227. ISSN: 0317-1671.  
PUB. COUNTRY: Canada  
DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200511  
ENTRY DATE: Entered STN: 18 Oct 2005  
Last Updated on STN: 15 Dec 2005  
Entered Medline: 30 Nov 2005

AB BACKGROUND: Interferon beta has become standard therapy for reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS). Several different preparations are available including interferon beta 1a (Avonex, Rebif) and interferon beta 1b (Betaferon/Betaseron). For the most part these preparations have been considered safe. Recently there have been concerns relating to liver and now kidney toxicity. CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon beta 1a. SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment. At its peak the daily protein loss was 35.82 g. Kidney biopsy demonstrated membranous glomerulonephritis. DISCUSSION: Two other case reports of nephrotic syndrome have been reported in the literature. This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.

L3 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:60234 CAPLUS <<LOGINID::20080408>>  
DOCUMENT NUMBER: 140:127206  
TITLE: Interferon b and human IgG1 Fc chimeric proteins  
for treating glomerulonephritis and chronic renal  
failure  
INVENTOR(S): Lobb, Roy R.  
PATENT ASSIGNEE(S): Biogen Inc., USA  
SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006756	A2	20040122	WO 2003-US22440	20030717
WO 2004006756	A3	20040819		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492649	A1	20040122	CA 2003-2492649	20030717
AU 2003256603	A1	20040202	AU 2003-256603	20030717
EP 1553971	A2	20050720	EP 2003-764795	20030717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681527	A	20051012	CN 2003-822107	20030717
JP 2005537269	T	20051208	JP 2004-521961	20030717
NZ 538217	A	20070427	NZ 2003-538217	20030717
BR 2003012947	A	20070710	BR 2003-12947	20030717
ZA 2005000342	A	20060726	ZA 2005-342	20050113
MX 2005PA00658	A	20050819	MX 2005-PA658	20050114
NO 2005000827	A	20050415	NO 2005-827	20050216
US 20070025965	A1	20070201	US 2005-521513	20051118
PRIORITY APPLN. INFO.: US 2002-396393P P 20020717				
WO 2003-US22440 W 20030717				

AB The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, glomerulonephritis or chronic renal failure. The methods involve the administration of IFN- $\beta$  therapeutics.

L3 ANSWER 29 OF 41 MEDLINE on STN DUPLICATE 6  
ACCESSION NUMBER: 2003331930 MEDLINE <<LOGINID::20080408>>  
DOCUMENT NUMBER: PubMed ID: 12862038  
TITLE: Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.  
AUTHOR: Tola Maria Rosaria; Caniatti Luisa Maria; Gragnaniello Daniela; Russo Monia; Stabellini Nevio; Granieri Enrico  
SOURCE: Journal of neurology, (2003 Jun) Vol. 250, No. 6, pp. 768-9.  
Journal code: 0423161. ISSN: 0340-5354.  
PUB. COUNTRY: Germany: Germany, Federal Republic of  
DOCUMENT TYPE: (CASE REPORTS)  
Letter  
LANGUAGE: English

FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200308  
ENTRY DATE: Entered STN: 17 Jul 2003  
Last Updated on STN: 28 Aug 2003  
Entered Medline: 27 Aug 2003

L3 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:282418 CAPLUS <<LOGINID::20080408>>  
DOCUMENT NUMBER: 138:270306  
TITLE: Use of interferon b in the therapy of systemic  
lupus erythematosus  
INVENTOR(S): Schwarting, Andreas; Galle, Peter R.  
PATENT ASSIGNEE(S): Germany  
SOURCE: PCT Int. Appl., 20 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028753	A1	20030410	WO 2002-DE3669	20020927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10148417	A1	20030417	DE 2001-10148417	20010929
AU 2002347065	A1	20030414	AU 2002-347065	20020927
PRIORITY APPLN. INFO.: DE 2001-10148417 A 20010929 WO 2002-DE3669 W 20020927				
AB Disclosed is the use of interferon b for the production of an agent for the prevention and treatment of SLE and improvement of kidney function, glomerulonephritis, proteinuria, splenomegaly, encephalomyelitis and collagen-induced arthritis, for the prevention of leukocyte infiltration and the prevention of IgG-deposits in kidneys. Said agent is particularly suitable for the treatment of SLE WHO-type IV.				
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L3 ANSWER 31 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2003:214384 USPATFULL <<LOGINID::20080408>>  
TITLE: 1,5-benzodiazepine compounds, their production and use  
INVENTOR(S): Oi, Satoru, Nara-shi, JAPAN  
Suzuki, Nobuhiro, Tsukuba-shi, JAPAN  
Matsumoto, Takahiro, Kawabe-gun, JAPAN

NUMBER	KIND	DATE
PATENT INFORMATION: US 2003149027 A1 20030807		

APPLICATION INFO.: US 2001-894105 A1 20010628 (9)

NUMBER DATE

PRIORITY INFORMATION: JP 1998-298941 19981020

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC,  
INTELLECTUAL

PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500,  
LINCOLNSHIRE, IL, 60069

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

LINE COUNT: 5350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the formula (I) ##STR1##

[wherein ring B represents a cyclic hydrocarbon group which may have substituent(s); Z represents hydrogen atom or a cyclic group which may have substituent(s); R.sup.1 represents hydrogen atom, a hydrocarbon group which may have substituent(s), a heterocyclic group which may have substituent(s) or an acyl group; R.sup.2 represents amino group which may have substituent(s); D represents a bond or a divalent group; E represents a bond, --CO--, --CON(R.sup.a)--, --COO--, --N(R.sup.a)CON(R.sup.b)--, --N(R.sup.a)COO--, --N(R.sup.a)SO.sub.2--, --N(R.sup.a)--, --O--, --S--, --SO-- or --SO.sub.2-- (R.sup.a and R.sup.b each independently represents hydrogen atom or a hydrocarbon group which may have substituent(s)); G represents a bond or a divalent group; L represents a bond or a divalent group; A represents hydrogen atom or a substituent; X and Y each represents hydrogen atom or an independent substituent; and . . . represents that R.sup.2 and an atom on ring B may form a ring] or a salt thereof, and a process for producing the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 41 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003241245 EMBASE <<LOGINID::20080408>>

TITLE: Recurrent nephrotic syndrome in patient  
with multiple sclerosis treated with interferon  
beta-1a [8].

AUTHOR: Tola, Maria Rosaria, Prof. (correspondence); Caniatti,  
Luisa Maria; Gragnaniello, Daniela; Russo, Monia; Granieri,  
Enrico

CORPORATE SOURCE: Department of Neurosciences, Azienda Osp. Univ. S. Anna,  
Corso della Giovecca, 203, CAP 44100 Ferrara, Italy.  
tlr@dns.unife.it

AUTHOR: Stabellini, Nevio

CORPORATE SOURCE: Nephrology Division, Azienda Osp. Univ. S. Anna, Corso  
della Giovecca, 203, CAP 44100 Ferrara, Italy.

SOURCE: Journal of Neurology, (1 Jun 2003) Vol. 250, No. 6, pp.

768-769.

Refs: 8

ISSN: 0340-5354 CODEN: JNRYA9

COUNTRY: Germany

DOCUMENT TYPE: Journal; Letter  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
028 Urology and Nephrology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
008 Neurology and Neurosurgery  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Jul 2003  
Last Updated on STN: 3 Jul 2003

L3 ANSWER 33 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2002:191539 USPATFULL <<LOGINID::20080408>>  
TITLE: Full-length human cDNAs encoding potentially secreted  
proteins  
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE

NUMBER KIND DATE

PATENT INFORMATION: US 2002102604 A1 20020801  
APPLICATION INFO.: US 2000-731872 A1 20001207 (9)

NUMBER DATE

PRIORITY INFORMATION: US 1999-169629P 19991208 (60)  
US 2000-187470P 20000306 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., Genset Corporation, 10665  
Sorrento Valley Road, San Diego, CA, 92121-1609  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Page(s)  
LINE COUNT: 28061  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such  
GENSET products may be used as reagents in forensic analyses, as  
chromosome markers, as tissue/cell/organelle-specific markers, in the  
production of expression vectors. In addition, they may be used in  
screening and diagnosis assays for abnormal GENSET expression and/or  
biological activity and for screening compounds that may be used in the  
treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2002:45607 USPATFULL <<LOGINID::20080408>>  
TITLE: 4,1-benzoxazepines, their analogues, and their use as  
somatostatin agonists  
INVENTOR(S): Mabuchi, Hiroshi, Nara, JAPAN  
Suzuki, Nobuhiro, Tsukuba, JAPAN  
Miki, Takashi, Osaka, JAPAN  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN  
(non-U.S. corporation)



	NUMBER	KIND	DATE
-----			
PATENT INFORMATION:	US 6352982	B1	20020305
	WO 9847882		19981029
APPLICATION INFO.:	US 1999-403066		19991014 (9)
	WO 1998-JP1797		19980420
			19991014 PCT 371 date

	NUMBER	DATE
-----		
PRIORITY INFORMATION:	JP 1997-103138	19970421
	JP 1997-319545	19971120
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kifle, Bruck	
ASSISTANT EXAMINER:	Liu, Hong	
LEGAL REPRESENTATIVE:	Riesen, Philippe Y., Chao, Mark	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	10436	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB The present invention provides a compound of the formula: ##STR1##		

wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R.sup.1 is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R.sup.2 is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, --CON(R.sup.a)--, --N(R.sup.a)CO--, --N(R.sup.b)CON(R.sup.c)--, --N(R.sup.d)COO--, --N(R.sup.e)SO.sub.2--, --COO--, --N(R.sup.f)--, --O--, --S--, --SO--, --SO.sub.2--, ##STR2##

(in which R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e and R.sup.f are respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group;

ring B may form an optionally substituted non-aromatic condensed nitrogen-containing heterocyclic ring by combining with R.sup.2; X is two hydrogen atoms, an oxygen atom or a sulfur atom; {character pullout} is a single bond or a double bond, and Y is a nitrogen atom when {character pullout} is a double bond, or an oxygen atom, --N(R.sup.4)-- (in which R.sup.4 is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group) or S(O).sub.n (in which n is 0, 1 or 2) when {character pullout} is a single bond, or a salt thereof, which have somatostatin receptor agonistic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 41 MEDLINE on STN DUPLICATE 7  
 ACCESSION NUMBER: 2002225336 MEDLINE <<LOGINID::20080408>>  
 DOCUMENT NUMBER: PubMed ID: 11961411  
 TITLE: Minimal change nephrotic syndrome

developing during postoperative interferon-beta therapy for malignant melanoma.

AUTHOR: Nakao Kazushi; Sugiyama Hitoshi; Makino Eiichi; Matsuura Hironori; Ohmoto Akiko; Sugimoto Taro; Ichikawa Haruo; Wada Jun; Yamasaki Yasushi; Makino Hirofumi  
CORPORATE SOURCE: Department of Medicine III, Okayama University Medical School, Japan.. onaka24@hotmail.com  
SOURCE: Nephron, (2002 Apr) Vol. 90, No. 4, pp. 498-500.  
Journal code: 0331777. ISSN: 0028-2766.  
PUB. COUNTRY: Switzerland  
DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200211  
ENTRY DATE: Entered STN: 19 Apr 2002  
Last Updated on STN: 11 Dec 2002  
Entered Medline: 20 Nov 2002

AB A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma. Renal pathologic findings were consistent with minimal change nephrotic syndrome (MCNS) showing extensive foot process effacement of visceral glomerular epithelial cells (podocyte). Nephrotic range proteinuria gradually regressed after stoppage of local injection of IFN-beta without glucocorticoid treatment. To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.  
Copyright 2002 S. Karger AG, Basel

L3 ANSWER 36 OF 41 USPATFULL ON STN  
ACCESSION NUMBER: 2001:197061 USPATFULL <<LOGINID::20080408>>  
TITLE: Dithiolin derivatives, their preparation and their therapeutic effect  
INVENTOR(S): Fujita, Takashi, Kashiwa, Japan  
Yokoyama, Tomihisa, Urawa, Japan  
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 6313164 B1 20011106  
APPLICATION INFO.: US 1999-354006 19990715 (9)  
RELATED APPLN. INFO.: Division of Ser. No. US 1998-52095, filed on 31 Mar 1998, now patented, Pat. No. US 6013663

NUMBER DATE

-----  
PRIORITY INFORMATION: JP 1997-83749 19970402  
JP 1998-8837 19980120  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Huang, Evelyn Mei  
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.  
NUMBER OF CLAIMS: 64  
EXEMPLARY CLAIM: 1  
LINE COUNT: 12721

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula (I): ##STR1##

wherein one of m and n is 0, and the other is 0, 1 or 2; k is 0 or 1 to 12; R.sup.1 is hydrogen, a substituent which is an aryl or a heterocyclic, or an optionally substituted alkyl group; A is a single bond, an oxygen atom, a carbonyl group or a group of the formula --N(R.sup.2)CO--, --N(R.sup.2)CS--, --N(R.sup.2)SO.sub.2--, --CON(R.sup.2)N(R.sup.3)CO--, --CON(R.sup.2)CO--, --CON(R.sup.2)CS--, --CON(R.sup.2)SO.sub.2--, --O--CO--, --ON(R.sup.2)CO--, --ON(R.sup.2)SO.sub.2--, --O--CON(R.sup.2)N(R.sup.3)CO--, --O--CON(R.sup.2)CO--, --O--CON(R.sup.2)SO.sub.2--, --CO--O--, --CO--CO--, --CO--CON(R.sup.2)N(R.sup.3)CO--, --CO--CON(R.sup.2)CO--, --CO--CON(R.sup.2)SO.sub.2--, --N(R.sup.2)O--, --N(R.sup.2)COCO--, --N(R.sup.2)N(R.sup.3)CO--, --N(R.sup.2)N(R.sup.3)SO.sub.2--, --N(R.sup.2)CON(R.sup.3)N(R.sup.4)CO--, --N(R.sup.2)CON(R.sup.3)SO.sub.2-- or --N(R.sup.2)CON(R.sup.3)SO.sub.2N(R.sup.4)CO--, wherein R.sup.2, R.sup.3 and R.sup.4 are the same or different and each is hydrogen, alkyl, aralkyl, acyl or a substituent a; B is a single bond, or a group of the formula --N(R.sup.5)-- or --N(R.sup.6)N(R.sup.5)-- wherein R.sup.5 and R.sup.6 are the same or different and each is hydrogen, alkyl, aralkyl, acyl or a substituent a, or R.sup.5, together with R.sup.1 and the nitrogen atom to which they are bonded form a heterocyclic ring having from 5 to 7 ring atoms; or R.sup.1 represents a group of formula --OR.sup.7, wherein R.sup.7 is alkyl, alkenyl, aralkyl or a substituent a; or R.sup.1 represents a hydroxy group or a group of the formula --OR.sup.7; or pharmaceutically acceptable salts thereof. The compounds enhance the activity of glutathione reductase and can be used for the treatment and prevention of a variety of diseases including cataracts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:530192 CAPLUS <<LOGINID:20080408>>

DOCUMENT NUMBER: 136:165888

TITLE: Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis

AUTHOR(S): Perez de Lema, Guillermo; Maier, Holger; Nieto, Elena; Vielhauer, Volker; Luckow, Bruno; Mampaso, Francisco; Schlondorff, Dettlef

CORPORATE SOURCE: Ludwig-Maximilians-Universitat, Munchen, D-80336, Germany

SOURCE: Journal of the American Society of Nephrology (2001), 12(7), 1369-1382

CODEN: JASNEU; ISSN: 1046-6673

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Lupus nephritis is characterized by immune complex deposition and inflammatory cell infiltration. Therefore, the initiation and progression of lupus nephritis in MRL/MpJ Faspr/lpr (MRL/lpr) mice were investigated, with a focus on the expression of several chemokines and chemokine receptors. Mice were monitored for proteinuria from 6 to 20 wk of age,

and kidneys were examined every 2 wk by light microscopy, electron microscopy, and immunohistol. analyses. Furthermore, the expression of chemokines, chemokine receptors, and proinflammatory cytokines was analyzed in RNase protection assays. MRL/lpr mice demonstrated increased expression of monocyte chemoattractant protein-1, regulated upon activation, normal T cell-expressed and -secreted protein (RANTES), inducible protein of 10 kDa (IP-10), and macrophage inflammatory protein-1b at week 8. At that time point, levels of circulating and glomerular immune complexes were increased, and no proteinuria or histopathol. signs of renal damage could be observed. As assessed in immunohistochem. and in situ hybridization analyses, monocyte chemoattractant protein-1 and RANTES expression were preferentially located in the glomeruli and interstitium. Mononuclear cell infiltration of the kidney was observed by weeks 10-12. At week 12, the renal expression of chemokine receptor 1 (CCR1), CCR2, and CCR5 was increased, mice became proteinuric, and renal damage was histol. evident. Finally, the expression of proinflammatory cytokines was detected (weeks 12-14). In summary, (1) chemokines are upregulated before inflammatory cell infiltration, proteinuria, and kidney damage are observed; (2) chemokine generation is restricted to sites of subsequent inflammatory cell infiltration, i.e., glomeruli and interstitium; (3) chemokine receptor expression parallels mononuclear cell infiltration; and (4) proinflammatory cytokines are upregulated later, in parallel with inflammatory cell infiltration and the onset of proteinuria. Thus, chemokines initiate leukocyte infiltration and precede proteinuria and renal damage in MRL/lpr mice.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 38 OF 41 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:330152 BIOSIS <<LOGINID::20080408>>

DOCUMENT NUMBER: PREV200200330152

TITLE: IFN-beta: A novel immunomodulating therapy of severe lupus nephritis.

AUTHOR(S): Schwarting, Andreas [Reprint author]; Paul, Kathrin [Reprint author]; Tschirner, Stephan [Reprint author]; Kriegsmann, Jorg; Mayet, Werner [Reprint author]; Wandel, Eveline [Reprint author]; Galle, Peter R. [Reprint author]

CORPORATE SOURCE: 1st Department of Medicine, University Hospital, Mainz, Germany

SOURCE: Journal of the American Society of Nephrology, (September, 2001) Vol. 12, No. Program and Abstract Issue, pp. 640A. print.

Meeting Info.: ASN (American Society of Nephrology)/ISN (International Society of Nephrology) World Congress of Nephrology. San Francisco, CA, USA. October 10-17, 2001. CODEN: JASNEU. ISSN: 1046-6673.

DOCUMENT TYPE: Conference; (Meeting) Conference; Abstract; (Meeting Abstract) Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Jun 2002  
Last Updated on STN: 12 Jun 2002

L3 ANSWER 39 OF 41 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN  
ACCESSION NUMBER: 2002:6478 BIOSIS <<LOGINID::20080408>>  
DOCUMENT NUMBER: PREV200200006478  
TITLE: Prophylaxis and therapy of severe lupus nephritis  
by interferon-beta treatment.  
AUTHOR(S): Schwarting, A. [Reprint author]; Tschirner, S. [Reprint  
author]; Paul, K. [Reprint author]; Kriegsmann, J.;  
Dederichs, E. [Reprint author]; Klingel, R. [Reprint  
author]; Wandel, E. [Reprint author]; Galle, P. R. [Reprint  
author]  
CORPORATE SOURCE: 1st Department of Medicine, University of Mainz, Mainz,  
Germany  
SOURCE: Kidney and Blood Pressure Research, (2001) Vol. 24, No.  
4-6, pp. 218. print.  
Meeting Info.: Joint Scientific Meeting of the Nephrology  
Society and the German Working Group for Clinical  
Nephrology. Munster, Germany. September 29-October 02,  
2001.  
ISSN: 1420-4096.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 28 Dec 2001  
Last Updated on STN: 25 Feb 2002

L3 ANSWER 40 OF 41 USPATFULL on STN  
ACCESSION NUMBER: 2000:4825 USPATFULL <<LOGINID::20080408>>  
TITLE: Dithiolan derivatives, their preparation and their  
therapeutic effect  
INVENTOR(S): Fujita, Takashi, Kashiwa, Japan  
Yokoyama, Tomihisa, Urawa, Japan  
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013663		20000111
APPLICATION INFO.:	US 1998-52095		19980331 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-83749	19970402
	JP 1998-8837	19980120

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Huang, Evelyn Mei  
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.  
NUMBER OF CLAIMS: 47  
EXEMPLARY CLAIM: 1  
LINE COUNT: 9846  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A compound of formula (I): ##STR1## wherein one of m and n represents 0,  
and the other represents 0, 1 or 2; k represents 0 or 1 to 12; R.sup.1  
is hydrogen, an aryl, a heterocyclic, an alkyl, a hydroxy or --OR.sup.7,  
wherein R.sup.7 is an alkyl, an alkenyl or an aralkyl; A is  
--CON(R.sup.2)SO.sub.2--, wherein R.sup.2 is hydrogen, an alkyl or an

aralkyl; B is a single bond; and pharmaceutically acceptable salts thereof. The compounds have the ability to enhance the activity of glutathione reductase and can therefore be used for the treatment and prevention of a variety of diseases including cataracts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 41 MEDLINE on STN  
 ACCESSION NUMBER: 91186537 MEDLINE <<LOGINID::20080408>>  
 DOCUMENT NUMBER: PubMed ID: 2082050  
 TITLE: Clinical and histological observation of HBV  
 glomerulonephritis treated with interferon-beta.  
 AUTHOR: Ueda T; Gotoh Y; Shiroshita K; Sakurai T; Kataoka Y  
 CORPORATE SOURCE: Department of Nephrology, Sapporo City General Hospital,  
 Japan.  
 SOURCE: Nippon Jinzo Gakkai shi, (1990 Nov) Vol. 32, No. 11, pp.  
 1153-9.  
 Journal code: 7505731. ISSN: 0385-2385.  
 PUB. COUNTRY: Japan  
 DOCUMENT TYPE: (CASE REPORTS)  
 (ENGLISH ABSTRACT)  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: Japanese  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199105  
 ENTRY DATE: Entered STN: 26 May 1991  
 Last Updated on STN: 26 May 1991  
 Entered Medline: 6 May 1991

AB Hepatitis B virus carriers, a 30-year-old man (case 1) and a 31-year-old man (case 2), associated with nephrotic syndrome were treated with interferon-beta. The nephrotic syndrome did not respond to corticosteroid therapy. Their HBs-Ag, HBe-Ag and HBe-Ag were positive. Renal biopsies revealed membranous glomerulonephritis in case 1 and mixed membranous and proliferative glomerulonephritis in case 2. Direct immunofluorescence studies showed strong granular staining of the GBM with IgG and using sandwich technique with anti-HBe antiserum, granular deposits were seen throughout the GBM. Patients were administrated mainly 3-6 x 10(6) IU/day interferon-beta intravenously for four weeks. After transitory elevation of serum transaminase, HBe-Ag and DNA-polymerase have disappeared with development of HBe-Ag (seroconversion) about six months after the end of interferon-beta administration. Then nephrotic syndrome has recovered in incomplete remission after a year and a half follow-up. The secondary renal biopsy in case 1 showed less intense deposits of HBe-Ag along GBM. These facts suggest that the improvement of proteinuria is associated with the decrease in HBV replication due to interferon therapy.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	111.09	111.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 11:07:49 ON 08 APR 2008